ReShape Lifesciences receives a patent allowance for a diabetes treatment system using vagus nerve modulation technology.
Quiver AI Summary
ReShape Lifesciences announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application related to a new Diabetes Neuromodulation system that utilizes proprietary vBloc™ technology for treating Type 2 diabetes. This patent, if granted, will provide protection until April 2039 and is part of a strong intellectual property portfolio of 62 patents addressing neuromodulation and glucose control. The technology aims to optimize glycemic control, potentially reducing medication reliance and associated treatment costs. ReShape's system employs bio-electronic methods to regulate insulin production and manage blood glucose levels. The company's core products, including the Lap-Band and Obalon systems, focus on effective obesity and metabolic disease treatments. Additionally, ReShape has entered an agreement to sell its assets, including the Diabetes Neuromodulation system, to Biorad Medisys.
Potential Positives
- ReShape Lifesciences received a Notice of Allowance for its patent application regarding a novel Diabetes Neuromodulation system, indicating strong progress in its technology development.
- The granted patent protection until April 12, 2039, strengthens the company's intellectual property portfolio and provides a competitive advantage in the medical technology market.
- The Diabetes Neuromodulation technology has demonstrated potential to significantly improve glycemic control in diabetes patients, which could lead to reduced reliance on medications and lower treatment costs.
- This announcement reflects the company’s commitment to innovative solutions in addressing Type 2 diabetes, underscoring its role as a leader in weight loss and metabolic health solutions.
Potential Negatives
- The announcement includes the significant detail that ReShape Lifesciences is selling substantially all its assets, which raises concerns about the company's future viability and business model.
- The sale of its Lap-Band® System and Obalon® Gastric Balloon System indicates a potential loss of core revenue-generating products that may impact financial stability.
- Despite receiving a Notice of Allowance for a promising patent, the effective ownership of the Diabetes Neuromodulation system will transfer to Biorad, limiting ReShape Lifesciences' control over what could be a critical technology for its business strategy.
FAQ
What is the purpose of ReShape Lifesciences' new patent?
The new patent focuses on a system for simultaneous multi-site vagus nerve modulation to improve glycemic control.
How does the Diabetes Neuromodulation system work?
The system utilizes bio-electronic neuromodulation to regulate blood glucose by modulating vagus nerve activity affecting the liver and pancreas.
What are the advantages of ReShape's technology over existing treatments?
The technology aims to lower treatment costs, reduce medication dependence, and minimize complications associated with Type 2 diabetes management.
When is the patent protection set to expire?
The patent protection for this technology is set to expire on April 12, 2039.
What is included in ReShape Lifesciences' intellectual property portfolio?
The portfolio includes 62 issued or pending patents covering various aspects of vagal neuromodulation, glucose control, AI, and Bluetooth applications.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RSLS Hedge Fund Activity
We have seen 0 institutional investors add shares of $RSLS stock to their portfolio, and 14 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GEODE CAPITAL MANAGEMENT, LLC removed 132,566 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $748,997
- VIRTU FINANCIAL LLC removed 58,913 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $332,858
- VANGUARD GROUP INC removed 49,874 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $281,788
- BLACKROCK, INC. removed 34,060 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $192,439
- HRT FINANCIAL LP removed 19,646 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $110,999
- STATE STREET CORP removed 13,015 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $73,534
- XTX TOPCO LTD removed 12,486 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $70,545
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
IRVINE, Calif., March 10, 2025 (GLOBE NEWSWIRE) --
ReShape Lifesciences
®
(Nasdaq: RSLS),
the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 17/046,677, entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control System and Methods.” When issued, the patent will provide protection until April 12, 2039. The Diabetes Neuromodulation system leverages its proprietary vagus nerve block (vBloc™) technology platform, along with vagus nerve stimulation, to treat Type 2 diabetes, a prominent disorder linked with obesity.
“Allowance for this newest patent, on the heels of the recently announced Israeli patent, serves as strong evidence of the promise of this groundbreaking technology, which has shown the potential to reduce dependence on medications for diabetics through a personalized approach. By optimizing glucose control, the technology aims to lower treatment costs and minimize complications related to poorly managed blood sugar and medication non-compliance,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences
®
. “Like other patent families within ReShape, the Diabetes Neuromodulation technology is supported by a robust intellectual property portfolio, comprising 62 issued or pending patents. These cover vagal neuromodulation, glucose control, AI, and Bluetooth applications, ensuring a clear path to commercialization while providing strong protection against competitive threats.”
“Type 2 diabetes is a worldwide issue and continues to be difficult to treat effectively, despite the availability of medication, surgery, and dietary interventions,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences. “ReShape’s Diabetes Neuromodulation technology regulates blood glucose by selectively modulating vagal block and stimulation to the liver and pancreas. Studies have shown improved glycemic control in both a Zucker rat model of Type 2 Diabetes Mellitus (T2DM) and an alloxan-treated swine model of T2DM. To date, our team has successfully completed the pre-clinical development of the device, employing bioelectronics to optimize insulin production and manage blood glucose levels in a personalized manner, with the potential to treat Type 2 diabetes and hypoglycemia.”
About The ReShape Diabetes Neuromodulation Device
The ReShape Diabetes Neuromodulation system (formerly, Diabetes Bloc-Stim Neuromodulation™ (DBSN™) is a novel minimally invasive therapeutic implant concept that delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation. The system utilizes a proprietary, reversable and adjustable electrical blockade that may represent the future of personalized medicine. Reshape Lifesciences believes its system is superior to both standalone stimulation of the vagus nerve, and vagus nerve ligation which has undesirable side effects and causes irreversible damage to the nerve.
About ReShape Lifesciences
®
ReShape Lifesciences
®
is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band
®
and Lap-Band
®
2.0 Flex Systems provide minimally invasive, long-term treatment of obesity and are an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The Obalon
®
balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
As previously announced ReShape has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., pursuant to which ReShape has agreed to sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape’s Lap-Band
®
System, Obalon
®
Gastric Balloon System and the DBSN™ system (but excluding cash). Therefore, at the closing of the transactions contemplated by the asset purchase agreement, the DBSN™ system will be owned by Biorad.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the promise of the Diabetes Neuromodulation technology and the potential path to commercialization of the technology. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
